Journal Article

Impact of Optimal Medical Therapy on Long-Term Outcomes After Myocardial Revascularization for Multivessel Coronary Disease

Kim, Mijin, Kim, Se Hee, Choi, Yeonwoo, Lee, Jinho, Kim, Hoyun, Park, Jinsun, Ahn, Jung-Min, Chung, Cheol-Hyun, Choo, Suk Jung, Kang, Do-Yoon, Park, Seung-Jung, Yoo, Jae-Suk, Park, Duk-Woo, Kim, Tae Oh, Kim, Joon Bum, Kim, Ho Jin

2023

Overview

Although optimal medical therapy (OMT) after coronary revascularization is advocated for intensive secondary prevention, its criteria and effect on long-term outcomes are uncertain. Using data from the ASAN-Multivessel (Asan Medical Center-Multivessel Revascularization) registry, we identified 8,311 patients who underwent coronary artery bypass grafting (CABG) (n = 3,115) or percutaneous coronary intervention (PCI) (n = 5,196). OMT was defined as the combination of minimum of 3 medications in 4 drug classes (antiplatelet drugs, statins, β blockers, and angiotensin-converting enzyme inhibitors or angiotensin receptor blockers). Two primary outcomes were all-cause mortality and serious composite outcome of death, spontaneous myocardial infarction, or stroke at 10 years. Of 8,311 patients, 4,321 (52.0%) followed OMT. In the 3,397 propensity-score-matched cohort, OMT status compared with non-OMT status was significantly associated with a lower risk of all-cause mortality (10.7% vs 18.7%; hazard ratio [HR] 0.55, 95% confidence interval [CI] 0.47 to 0.65) and serious composite outcome (14.5% vs 22.5%, HR 0.635, 95% CI 0.55 to 0.73) at 10 years. The association on 10-year mortality was more prominent in the PCI group (HR 0.45, 95% CI 0.36 to 0.56) than in the CABG group (HR 0.72, 95% CI 0.58 to 0.90) with a significant interaction (p = 0.001). Overall findings were consistent using different OMT criteria (all 4 types of medications). In conclusion, OMT significantly lowered the risks of mortality and major cardiovascular events at 10 years in patients with multivessel revascularization. The OMT impact on mortality was more remarkable in the PCI group than in the CABG group. This work was registered at http://ClinicalTrials.gov (Identifier: NCT02039752).

• Publisher: Elsevier Inc,Elsevier Limited
• Subject: Angiotensin / Angiotensin-converting enzyme inhibitors / Bypass / Cardiovascular disease / Cardiovascular diseases / Cerebral infarction / Clinical outcomes / Coronary artery / Coronary Artery Bypass - adverse effects / Coronary Artery Disease / Coronary vessels / Criteria / Endocrine system / Enzymes / Health care facilities / Heart diseases / Heart surgery / Humans / Mortality / Myocardial infarction / Myocardial Infarction - etiology / Myocardial Revascularization / Peptidyl-dipeptidase A / Percutaneous Coronary Intervention - adverse effects / Statins / Stroke / Treatment Outcome / Variables